Product Information

TRIUMEQ 600-50-300 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $130.1327 per EA under NDC 49702023113. Its NADAC has been published 610 times since Dec 17, 2014.

FDA first approved this application on Aug 22, 2014.

TRIUMEQ 600-50-300 MG TABLET

abacavir sulfate, dolutegravir sodium, lamivudine
$130.1327per EA

Strength

600; 50; 300 mg/1; mg/1; mg/1

NDC

49702023113

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA205551

FDA Approved

8/22/2014

On Market Since

8/22/2014

Pharmacological Classes

Cytochrome P450 1A1 Inhibitors
HIV Integrase Inhibitors
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Multidrug and Toxin Extrusion Transporter 1 Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Organic Cation Transporter 2 Inhibitors

Price Statistics

The NADAC for TRIUMEQ 600-50-300 MG TABLET has been published 610 times since Dec 17, 2014, and over the history we have for it it has risen 83.8%. The table below summarizes its recorded NADAC range and movement.

Current price$130.1327 per EA
All-time high$130.1327 (Aug 19, 2026)
All-time low$70.8135 (Dec 17, 2014)
52-week high$130.1327
52-week low$126.1045
Median price$98.1887
Average price$100.3817
Largest weekly change+7.9% (Feb 8, 2017)
Weeks tracked610
Tracking sinceDec 17, 2014

Price History

1W

+0.0%

1M

+0.0%

3M

+0.0%

6M

+0.1%

1Y

+3.2%

3Y

+13.6%

5Y

+26.3%

All

+83.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the abacavir sulfate, dolutegravir sodium, lamivudine market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of TRIUMEQ 600-50-300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for TRIUMEQ 600-50-300 MG TABLET, manufactured by ViiV Healthcare Company, is $130.1327 per EA (NDC 49702023113), effective Aug 19, 2026.

How has the price of TRIUMEQ 600-50-300 MG TABLET changed over time?

Over the history we have for it, the NADAC for TRIUMEQ 600-50-300 MG TABLET has risen 83.8%. It has been tracked across 610 weekly CMS publications since Dec 17, 2014.

What are the highest and lowest recorded NADAC prices for TRIUMEQ 600-50-300 MG TABLET?

Since Dec 17, 2014, the NADAC for TRIUMEQ 600-50-300 MG TABLET has ranged from a low of $70.8135 (Dec 17, 2014) to a high of $130.1327 (Aug 19, 2026), with a median of $98.1887 per EA.

Are there cheaper alternatives to TRIUMEQ 600-50-300 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of TRIUMEQ 600-50-300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures TRIUMEQ 600-50-300 MG TABLET?

TRIUMEQ 600-50-300 MG TABLET (NDC 49702023113) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.